News & Events



BD FACSArray™ Bioanalyzer is Honored with a 2004 Silver Industrial Design Excellence Award


 Image Technological Innovation in Flow Cytometry from BD

Contact: Lisa English, PhD
BD Biosciences, Strategic Communications
(408) 954-2339

Tony  Ward
BD Biosciences Pharmingen, Marketing
(858) 812-8862

San Jose, CA (June 28, 2004) -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced that it has won a Silver IDEA04 for its new BD FACSArray™ bioanalyzer. The Industrial Design Excellence Awards (IDEA) are co-sponsored by the Industrial Designers Society of America (IDSA) and BusinessWeek, and are dedicated to fostering business and public understanding of the importance of industrial design excellence to the quality of life and the economy.

Select IDEA04 winners are highlighted in the July 5th issue of BusinessWeek. A complete list of IDEA04 winners can be found in BusinessWeek online. IDSA's quarterly magazine, Innovation, will publish information on IDEA04 winners in its Yearbook in the fall. In addition, as a Silver IDEA04 winner, BD Biosciences will participate in the IDEA product exhibit at the IDSA's 2004 Design Gallery during the IDSA national conference in Pasadena, CA, October 27-30, 2004.

"Winning a Silver IDEA04 is a tremendous honor," said Kip Miller, Vice President and General Manager of BD Biosciences Pharmingen. "The BD FACSArray™ bioanalyzer's design was based on identified user needs and market trends. We hope the design of this system will make flow cytometry accessible to a wider range of life science researchers and will help advance biomedical discovery."

The BD FACSArray™ bioanalyzer is a compact, benchtop flow cytometry system for fast, sensitive high-content analysis of cells and proteins in cell biology, immunology, and drug discovery. It includes an integrated 96-well plate sampler, an optical detection unit, a computer workstation, acquisition and analysis software, and recommended applications.

As a new, powerful, and lower-cost flow cytometry system featuring near "plug and play" simplicity, the bioanalyzer was given a distinctive design consistent with user needs and market trends, such as automation, higher throughput, smaller sample volumes, precision, and multiplexing of data. Special effort was undertaken to design an intuitive user interface to support fast adoption in a broad range of laboratory settings.

One of the most significant benefits of this system is high sampling speed, which is achieved by combining novel plate sampler technology with digital electronics, generating acquisition rates of up to 15,000 events per second. A 96-well plate can be run in less than 35 minutes. Also, while most instruments of this nature use sample tubes, the BD FACSArray™ bioanalyzer uses a microtiter plate, requiring smaller sample volumes.

The system's design offers other benefits, including a small product footprint and recessed I/O panel that conserves highly valuable benchtop space, location of the microtiter plate sampler in the corner of the instrument to allow both front manual sample and side robotic sample loading modes by simply rotating the instrument 90 degrees, and convenient access to fluid reservoirs and fluidics filters.

In addition, the design of the BD FACSArray™ bioanalyzer helps users avoid some of the repetitive manual manipulations frequently associated with laboratory research. Overall, the bioanalyzer is an easy-to-use system, offering one-click maintenance protocols as well as system software to drive instrument control and support walk-away sample acquisition and batch analysis.

The BD FACSArray™ bioanalyzer has also been honored with a Bronze award in the IDSA Northwest Invitational Design Competition and was a winner in the medical category of Appliance Manufacturer Magazine's Excellence in Design competition.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. For the fiscal year ended September 30, 2003, BD reported total revenues of $4.528 billion.

For more information about the BD FACSArray™ bioanalyzer, visit www.bdbiosciences.com.

# # #

For Research Use Only. Not for use in diagnostic or therapeutic procedures.



This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; BD's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

 

Unless otherwise noted, BD, BD logo and all other trademarks are property of Becton Dickinson and Company. © 2013 BD